Targeted antibody combo aims to shrink HER2-Positive stomach cancers before surgery
Disease control
Not yet recruiting
This trial investigates whether adding the targeted antibody zanidatamab to standard chemotherapy can shrink HER2-positive stomach or gastroesophageal junction cancers before surgery. It includes two groups: people with locally advanced cancer that has not spread, and those with …
Phase: PHASE2 • Sponsor: Zhifeng Zhao, PhD • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC